In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colombia first country to eliminate river blindness, using Merck's ivermectin

This article was originally published in Scrip

Executive Summary

Colombia has become the first country in the world to eliminate the parasitic disease onchocerciasis (river blindness), using a variety of approaches including treatment with Merck's ivermectin, education measures and improvements in living conditions and basic sanitation, according to the World Health Organization (WHO).

You may also be interested in...



Coronavirus Notebook: New Nordic Studies, Vaccine Solidarity Pledges, And The Re-Start Of COPCOV

As the US snaps up most supplies of remdesivir, the EU says it is committed to ensuring global access to coronavirus medicines and international donors have been asked to pledge more money to pay for vaccines, medicines and tests. The past week has also seen some ups and downs for trials of various products for the treatment or prevention of COVID-19. 

EU Sees Drug Shortage Risk From COVID-19 Second Wave

A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

Drug Shortage Threat From Second COVID-19 Wave

A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

Topics

UsernamePublicRestriction

Register

LL082593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel